[{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Parion Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hypertonic Saline","moa":"Electrolyte\/osmotic gradient","graph1":"Genetic Disease","graph2":"Phase I","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"The University of Pittsburgh School of Medicine \/ Parion Sciences","highestDevelopmentStatusID":"6","companyTruncated":"The University of Pittsburgh School of Medicine \/ Parion Sciences"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"||Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Erlotinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ OSI PHARMS","highestDevelopmentStatusID":"6","companyTruncated":"The University of Pittsburgh School of Medicine \/ OSI PHARMS"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The University of Pittsburgh School of Medicine \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ Leo Pharma"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Gate Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glycerol Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase I","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"The University of Pittsburgh School of Medicine \/ Amgen Inc"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health | Reckitt Benckiser | National Center for Research Resources","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health | Reckitt Benckiser | National Center for Research Resources","highestDevelopmentStatusID":"8","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health | Reckitt Benckiser | National Center for Research Resources"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"I-123 Metaiodobenzylguanidine","moa":"Norepinephrine transporter (NET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The University of Pittsburgh School of Medicine \/ GE Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ GE Healthcare"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"PDX1\/MAFA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"The University of Pittsburgh School of Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ OSI PHARMS","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ OSI PHARMS"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PittCoVacc","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"The University of Pittsburgh School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pasireotide Diaspartate","moa":"Somatostatin receptor 5 | Somatostatin receptor 3 | Somatostatin receptor 2 | Somatostatin receptor 1","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"The University of Pittsburgh School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ab8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Waste Connections Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Gamma Glutamylcysteine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Waste Connections Inc","highestDevelopmentStatusID":"6","companyTruncated":"The University of Pittsburgh School of Medicine \/ Waste Connections Inc"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ Sanofi"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"IVIG","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Perelel Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Perelel Prenatal Vitamin","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Perelel Inc.","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Perelel Inc."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PiN-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"The University of Pittsburgh School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"The University of Pittsburgh School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Alaska Native Tribal Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Resistant Starch","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Alaska Native Tribal Health Consortium","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Alaska Native Tribal Health Consortium"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genentech"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The University of Pittsburgh School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"}]
Find Clinical Drug Pipeline Developments & Deals by The University of Pittsburgh School of Medicine
Details :
Gamma Glutamylcysteine is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Parkinson Disease.
Details :
Perelel Prenatal Vitamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Pregnancy.
Details :
The collaboration aims the initiation of a Phase 2 to assess the potential for extending the efficacy of GATE-202 (apimostinel), a rapid-acting antidepressant drug.
Details :
Companies are expanding this agreement to include engineering of NK cells to generate SNAP-CAR NK therapies, to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.
Details :
Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 di...
Details :
University of Pittsburgh grants Genprex a preclinical technology that transforms macrophages, complementary to the GPX-002 diabetes technology. Novel infusion process uses an endoscope and an AAV vector with a glucagon promoter to deliver the Pdx1 + MafA...
Details :
The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas.
Details :
Diabetic mice studies have shown that GPX-002, a gene therapy for diabetes, restored normal blood glucose levels for an extended period of time, which could translate to decades in humans.
Details :
Preclinical research in a syngeneic solid tumor mouse model shows that I/ONTAK (E7777 or denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 therapy.
Details :
Current SNAP-CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.
Reset All
